John B. Bode is Director at ZEVRA THERAPEUTICS, INC. (ZVRA). They have made 6 open-market trades across 2 companies since 2014, most recently 2026-09-29.
CIK 0001612084
Unrated. We grade insiders only on stock they chose to buy on the open market. Grants, option exercises and vesting say nothing about timing, so they don't count — which is why someone can file often and still have no grade. It isn't a bad sign: unrated buys beat every graded tier below A.
6 open-market purchases totalling $337K since 2014, never a sale. Across 5 scored buys the stock is up 4.2% at ninety days, and 0.4 points ahead of the S&P over the same stretch.
5 scored purchases · one row per filing · discretionary only
| 7d | 30d | 90d | |
|---|---|---|---|
| Accuracy | 0% | 40% | 60% |
| Avg Move | -5.2% | -5.3% | +4.2% |
| Alpha | -4.4% | -3.8% | +0.4% |
| Scored | 5 | 5 | 5 |
| Ticker | Type | Traded | Filed | Price | Value | 7d Stock | 30d Stock | 90d Stock |
|---|---|---|---|---|---|---|---|---|
| ZVRA | BUY | 2025-08-19 | 2025-08-20 | $9.17 | $46K | -4.6% | -19.6% | +1.7% |
| ZVRA | BUY | 2025-03-19 | 2025-03-21 | $7.96 | $80K | -8.0% | -17.5% | +8.5% |
| ZVRA | BUY | 2024-07-12 | 2024-07-15 | $5.87 | $59K | -5.9% | +5.6% | +22.1% |
| ZVRA | BUY | 2023-09-05 | 2023-09-06 | $5.13 | $51K | -0.2% | -7.8% | -0.8% |
| ZVRA | BUY | 2023-05-18 | 2023-05-19 | $5.04 | $50K | -7.1% | +12.7% | -10.3% |
| TPUB | BUY | 2014-11-11 | 2014-11-12 | $16.99 | $51K | N/A | N/A | N/A |
Grouped by shared companies and similar filing behaviour. This is a similarity measure, not a ranking or a performance signal.